Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis

American Journal of Pathology

Volumn 168, Issue 4, 2006, Pages 1086-1096

  Fujimoto, Hajime ^a   Gabazza, Esteban C ^a   Taguchi, Osamu ^a,e   Nishii, Yoichi ^a   Nakahara, Hiroki ^a   Bruno, Nelson E ^a   D'Alessandro Gabazza, Corina N ^a   Kasper, Michael ^b   Yano, Yutaka ^a   Nagashima, Mariko ^c   Morser, John ^c   Broze, George J ^d   Suzuki, Koji ^a   Adachi, Yukihiko ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c BAYER AG   (Germany)

^d BARNES JEWISH HOSPITAL   (United States)

^e MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; BLEOMYCIN; CHEMOKINE; COLLAGEN; CYTOKINE; ELASTASE; FIBRINOGEN; GRANULOCYTIC MACROPHAGE GROWTH FACTOR; GROWTH FACTOR; HYDROXYPROLINE; INTERLEUKIN 13; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HETEROZYGOTE; HISTOPATHOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LUNG FIBROSIS; LUNG LAVAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR DEFICIENCY; WILD TYPE;

EID: 33645451489     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050610     Document Type: Article

References (36)

1. Canonico AE, Brigham KL: Biology of acute lung injury. The Lung, ed 2. Edited by RG Crystal, PJ Barnes, JB West, ER Weibel. Philadelphia, Lippincott-Raven, 1997, pp 2475-2498
2. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA: The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000, 157:177-187
3. Chambers RC: Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J Suppl 2003, 44:33s-35s
4. Saksela O, Rifkin DB: Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988, 4:93-126
5. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman Jr HA: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990, 322:890-897
6. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989, 84:695-705
7. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF: Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000, 106:1341-1350
8. Loskutoff DJ, Quigley JP: PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000, 106:1441-1443
9. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O: Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001, 163:1660-1668
10. Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, Ido M, Shimizu T, Nakagaki T, Kobayashi H, Fukudome K, Tsuneyoshi N, D'Alessandro-Gabazza CN, Izumizaki M, Iwase M, Homma I, Adachi Y, Suzuki K: Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003, 167:1416-1426
11. Colwell JA, Jokl R: Vascular thrombosis in diabetes. Diabetes Mellitus. Edited by D Porte, RS Sherwin, Stamford, Appleton & Lange, 1997, pp 207-216
12. Bajzar L: Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000, 20:2511-2518
13. Fujimoto H, Gabazza EC, Hataji O, Yuda H, D'Alessandro-Gabazza CN, Nakano M, Franco OE, Hayashi T, Suzuki K, Adachi Y, Taguchi O: Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am J Respir Crit Care Med 2003, 167:1687-1694
14. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze Jr GJ, Fay WP, Morser J: Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002, 109:101-110
15. Meyer KC, Zimmerman JJ: Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993, 121:654-661
16. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH: Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol 2002, 283:L1023-L1032
17. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH: Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003, 163:445-452
18. Gabazza EC, Kasper M, Ohta K, Keane M, D'Alessandro-Gabazza C, Fujimoto H, Nishii Y, Nakahara H, Takagi T, Menon AG, Adachi Y, Suzuki K, Taguchi O: Decreased expression of aquaporin-5 in bleomycin-induced lung fibrosis in the mouse. Pathol Int 2004, 54:774-780
19. Riches DWH, Worthen GS, Augustin A, Lapadat R, Chan ED: Inflammation in the pathogenesis of interstitial lung disease. Interstitial Lung Disease. Edited by MI Schwarz, TE King. Hamilton, BC Decker Inc., 2003, pp 187-220
20. Chapman HA: Disorders of lung matrix remodeling. J Clin Invest 2004, 113:148-157
21. Mutch NJ, Moore NR, Wang E, Booth NA: Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003, 1:2000-2007
22. Strieter RM, Belperio JA, Keane MP: CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol 2003, 29:S67-S69
23. Idell S, James KK, Gillies C, Fair DS, Thrall RS: Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989, 135:387-399
24. Skogen WF, Senior RM, Griffin GL, Wilner GD: Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988, 71:1475-1479
25. Senior RM, Skogen WF, Griffin GL, Wilner GD: Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986, 77:1014-1019
26. Liu X, Piela-Smith TH: Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000, 165:5255-5261
27. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H: FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Blood 1991, 77:94-100
28. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL: Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 1984, 117:418-428
29. Thompson WD, Stirk CM, Melvin WT, Smith EB: Plasmin, fibrin degradation and angiogenesis. Nat Med 1996, 2:493
30. Agostini C, Siviero M, Semenzato G: Immune effector cells in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 1997, 3:348-355
31. Keane MP, Belperio JA, Strieter RM: Cytokine biology and the pathogenesis of interstitial lung disease. Interstitial Lung Disease. Edited by MI Schwarz, TE King. Hamilton, BC Decker Inc., 2003, pp 245-275
32. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL: Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278:51059-51067
33. Campbell W, Okada N, Okada H: Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001, 180:162-167
34. Ploplis VA, Wilberding J, McLennan L, Liang Z, Cornelissen I, DeFord ME, Rosen ED, Castellino FJ: A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol 2000, 157:703-708
35. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J: Mechanisms for pro matrix metalloproteinase activation. APMIS 1999, 107:38-44
36. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, Simon RH, Nakamura T, Miyake M: The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004, 164:1091-1098